Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$30.33 USD
-0.13 (-0.43%)
Updated May 31, 2024 04:00 PM ET
After-Market: $30.34 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 21 - 40 ( 720 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Preliminary FY23 Results; Ushering in the New Year with a New CEO at the Helm
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Stock Historically Cheap; Street Apathetic to Takeout Potential Down Here
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Near- Long-Term EXPAREL Growth Drivers Intact; Gross Margins Still a Focus
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2Q23: Lowered Guide Clears Street''s Low Bar, Making Stock Easier to Own for 2H Upturn; PT to $63; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Near-Term Focus Remains on Improving Gross Margins Driving EXPAREL Growth; Q2
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Low Street 2Q Expectations; We Don?t Expect Lowered Guide; Potential Near-Term CMS Upside; PT to $68; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O